Loading clinical trials...
Loading clinical trials...
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
I-131-CLR1404
dexamethasone
+1 more
Locations
4
United States
Mayo Clinic
Jacksonville, Florida, United States
Loyola University Medical Center
Maywood, Illinois, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Start Date
February 1, 2015
Primary Completion Date
December 9, 2020
Completion Date
August 10, 2022
Last Updated
February 22, 2023
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Cellectar Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions